Connected, brainy, athletic: the suspect in US insurance CEO's slayingLast week, I went to the Originator Connect holiday party and conference in Irvine. It was a good opportunity to sniff out innovative mortgage financing tools aimed at helping consumers just like you. For me, the find of the day was a home equity line of credit (HELOC) allowing bank statement deposits to be used as an income qualifying substitute for tax returns. I’ve come across bank statement fixed-rate second mortgages, where an applicant must pull all the money out at once, but I’ve never come across this concept for HELOCs. The big advantage with a HELOC is it allows you to borrow and pay it back, sort of like a business line of credit or a credit card, but at significantly cheaper rates. Many self-employed borrowers can show a nice flow of income through bank deposits, but the money doesn’t translate well enough when it comes to claiming enough qualifying net income on a tax return. Legitimate (or even illegitimate) expenses claimed on tax returns whittle down the taxable income. Hence, the bank statement loan program works for those who are unable to meet “full documentation” income and debt-ratio qualifications. What’s the catch? A borrower is going to pay a higher rate and more fees on this HELOC compared with a standard bank HELOC. Beggars can’t be choosers. If you can’t get a bank HELOC, you may be able to get a bank statement HELOC. Here’s an example: $500,000 loan, 75% loan-to-value and 740 middle FICO score offers a start rate of 10.125%. Assume points and closing costs of $7,000. Compare that to a full doc (tax returns to provide the income) bank HELOC, to which you might be paying zero costs with a starting rate of 8.25%. Among the program highlights: This twist on a HELOC is available for owner-occupied residences, second homes and investment properties. The maximum loan amount is $750,000. The borrower must pull out at least 80% of the line amount at closing. You cannot pay any of it back for 90 days. It’s a 20-year term. You can borrow and pay back for the first five years at interest-only payments. A borrower will have an additional 15 years to pay the line back. Also, you can pull out as much as 85% of the equity from your property. American Business Media (the conference organizer) arranges 30 shows a year around the United States. I asked the director of events, Navindra Persaud, what was the hottest topic for mortgage brokers these days. “Navigating higher (mortgage) rates and finding diversity to their (consumer) product offerings,” he told me. Speaking of diversity, another very interesting program is another version of fog-the-mirror lending (if you can fog a mirror, we’ll give you a loan). If you have the same or more liquid assets compared with the loan balance, no questions are asked about any job or income. That section of the application is left blank. For example, you are applying for a $750,000 mortgage. You are currently unemployed. And you can show $750,000 of money between your bank and brokerage accounts. You qualify for this fog-the-mirror-2.0 loan. As an aside, fog-the-mirror 1.0 includes no job or income, just nine months of payment reserves and excellent credit. No need to be able to match your mortgage balance with your liquid assets. Fog the mirror 1.0 carries a 8-8.5% interest rate on a 30-year fixed with about 2 points cost. The version 2.0 rate is between 7.5% and 8% with 2 points. Related Articles Housing | 30-year mortgage down to October levels at 6.69% Housing | Privatizing Fannie Mae would cause mortgage rates to soar, economist says Housing | FHFA loan limits rising to $1.2 million in LA and OC, top $806,000 in Inland Empire Housing | California affordability fixes: 3.5% loans, 50% raises, or 33% home-price cuts? Housing | ‘Difference is Trump’: American homebuyers brace for rate pain Mixed-use: More and more new buildings are offering a combination of retail space and homes. Industry jargon for this is “mixed use.” For the most part, it’s hard to find mixed-use financing. One lender allows residential or commercial zoning for two to eight units, with a loan amount up to $2 million. Not bad. The rate is roughly 7.25% for a 30-year fixed with 2 points. Foreign borrowers: ITIN (individual taxpayer identification number) in lieu of a Social Security number, DACA and foreign national loans all were on display. The foreign national loan required zero U.S. credit, so long as the borrower is putting at least 30% down. The investor-borrower cannot reside in the U.S. Talk about the world being your oyster. When mortgage shopping and there seems to be nothing you want or need, be sure to have at least three mortgage brokers tell you the same thing: “It’s not out there.” Otherwise, keep looking, because you just might find a program that fits your needs. The 30-year fixed rate averaged 6.69%, 12 basis points lower than last week. The 15-year fixed rate averaged 5.96%, 14 basis points lower than last week. The Mortgage Bankers Association reported a 2.8% mortgage application increase compared with one week ago. Bottom line: Assuming a borrower gets the average 30-year fixed rate on a conforming $806,500 loan, last year’s payment was $183 more than this week’s payment of $5,199. What I see: Locally, well-qualified borrowers can get the following fixed-rate mortgages with one point: A 30-year FHA at 5.625%, a 15-year conventional at 5.5%, a 30-year conventional at 6.25%, a 15-year conventional high balance at 5.99% ($806,501 to $1,209,750 in LA and OC and $806,501 to $1,077,550 in San Diego), a 30-year-high balance conventional at 6.5% and a jumbo 30-year fixed at 6.375%. Eye-catcher loan program of the week: A 30-year mortgage, with 30% down locked for the first 5 years at 5.875% with 1 point cost. Jeff Lazerson, president of Mortgage Grader, can be reached at 949-322-8640 or jlazerson@mortgagegrader.com .Walmart is dropping huge markdowns on TV during its “Black Friday Deals” sale and the discount on this massive 75-inch 4K UHD TV model is super cheap. Starting on Nov. 25, the 75-inch VIZIO 4K UHD LED HDR TV is on sale for $478, instead of $598, for a savings of $120 off. Related: Walmart’s Black Friday has the best deals of the season with up to 70% off — including these 21 holiday steals Walmart is kicking off its mega “Black Friday Deals” sale online on Monday, Nov. 25 at 5 p.m. ET, with exclusive access for Walmart+ members at 12 p.m. ET. Deals start in stores on Nov. 29 at 6 a.m. local time. This is a huge Black Friday discount on a massive-sized 75-inch VIZIO TV with 4K UHD resolution and a real-life picture quality with an extensive color range and detail. Dolby Audio provides cinema-quality sound to the TV, with Dolby Atmos compatibility also included. The 75-inch VIZIO TV supports WiFi6 for improved streaming and gaming performance with access to your favorite streaming channels and free TV content with the built-in WatchFree+ app. Video game play is also enhanced with the Dolby Vision HDR Gaming feature that has automatic latency detection and voice control is enabled with the VIZIO app on your Android or iOS devices and Shop for this 75-inch VIZIO 4K UHD LED HDR TV deal at Walmart here. Walmart Black Friday TV Deals You can also check out more TVs on sale at Walmart during its “Black Friday Deals” sale, including these popular models: Shop for even more markdowns from Walmart’s big “Black Friday Deals” sale here. The Best Black Friday Deals in 2024 Our journalism needs your support. Please subscribe today to NJ.com . Dawn Magyar can be reached at dmagyar@njadvancemedia.com . Have a tip? Tell us at nj.com/tips/ .

Another complaint filed with ICT against Hasina, 32 others

Lauren is a thought leader in Digital Journal’s Insight Forum ( become a member ). Accuracy, fairness, and independence have long defined journalistic standards. As newsrooms embrace data-driven processes with open arms, human judgment, independence, and expertise are confronted by algorithmic systems that prioritize optimization over traditional journalistic values. The rise of algorithms has reshaped journalism, raising urgent questions about journalistic authority and who controls the narrative. Journalistic language is evolving — from informing audiences to appeasing search engines — where traditional values now bow to production demands. With an increased access to information comes an increased competition to be found , trusted and read . The grounding of human judgment, independence and expertise is now confronted by clouded algorithmic requirements in order to get a journalist’s perspective front and centre. What difference, if any, do these human standards make when machines become essential members of the news-production team? How are these principles transformed when algorithms are introduced into journalism, influencing everything from story selection to content distribution? From story selection to distribution, algorithms now shape every stage of the news cycle, guided by audience-engagement metrics. While technology is often seen and understood as objective, algorithms are fundamentally influenced by the values of their human creators and the datasets they have selected. This becomes particularly controversial when these algorithms are then introduced as a way to prioritize content in the newsroom based on predictions of potential audience engagement. Social media platforms have become gatekeepers of news, with algorithms deciding what content gets seen. This reliance forces newsrooms to prioritize algorithm-friendly content, often at the expense of journalistic integrity and independence. The prioritization of sensationalism over depth, or even fact, as well as the offer of personalization, become unintended consequences of adopting an “objective” technology, slowly but surely eroding journalistic integrity in favour of click-driven content. The algorithmic landscape’s first substantive challenge to journalistic standards lies in exacerbating an already complex tension: the aspiration for impartiality versus the need for engagement. With algorithms dictating publication and distribution, journalists face mounting pressure to craft stories that inform — and captivate. This balancing act is further complicated by the ways algorithms shape not just distribution but also the content itself. When it comes to the actual articles we read, the impact of algorithms becomes more concerning still as we are seeing a new trend in automated articles created by large language models and algorithmic compilations of content. Automated journalism excels at summarizing data but lacks the nuance, depth, and critical perspective that define high-quality reporting. This of course can lead to fears of replacing journalists and eroding diverse human perspectives. In a surprising turn of events, it is precisely the human bias, the lack of perceived objectivity, that gives journalism the edge over tech-generated content. It is human judgment, contextual understanding and the ethical considerations of journalists that the algorithms cannot replicate. Consider, for example, a breaking news story about a local protest. An algorithm might prioritize articles based on engagement metrics — boosting headlines that feature sensational phrases like “clashes erupt” or “violent riots.” However, a journalist on the ground brings a nuanced perspective: they can recognize the protest’s underlying social and economic issues, interview participants to understand their motivations, and ensure that the coverage reflects diverse voices, not just the most clickable angles. Algorithms lack the ability to question the narratives it promotes or to see beyond the data. This is where human judgment is indispensable — it ensures that the story isn’t reduced to a sensational headline but instead provides readers with a comprehensive understanding of the event, fostering informed discourse rather than polarization. Maintaining this positionality in light of the previous argument for click-based sensationalism then becomes a challenge to journalistic authority and authenticity — is it still journalism if accuracy and public interest are challenged by engagement-based models? Transparency and disclosure have emerged as central themes in our analysis. As algorithms become more embedded in journalism, the need to openly acknowledge their influence on news production finds itself rising to the forefront. Despite its growing influence, the industry struggles to disclose algorithmic involvement to audiences. Without proper disclosure, the lines between human editorial judgment and algorithmic decision-making blur, raising serious ethical questions. We have all heard at this point that bias and transparency are not exactly strong points for algorithms, especially given that they are trained on historical (and historically biased) data. The perpetuation and exacerbation of societal biases and inequalities then becomes even more prevalent in the magnifying glass that is large data models and artificial intelligence. Disclosure of use of algorithms and AI to generate content and push it to readers is not something that is yet regulated which puts the responsibility back on the company and its readership to determine accountability for transparency and erosion of the human in the loop. To me, the human in the loop represents more than just oversight — it’s about maintaining a vital connection between technology and humanity. It’s the journalist’s ability to apply ethics, context, and critical thinking to ensure the stories we consume reflect the complexity of the world, not just the calculations of an algorithm and the priorities of the people who created it. Without this human element, journalism risks losing the empathy and insight that make it more than just a delivery system for information — it becomes the soul of storytelling itself. We are now living in an era where perception often is reality, especially in journalism and media. The way stories are framed, the headlines we scroll past, and the platforms that surface them shape what audiences believe to be true. Algorithms, designed to optimize for engagement, have exacerbated this phenomenon by prioritizing content that aligns with existing biases, incites strong emotions, or simply keeps users scrolling. In this system, the loudest voices and most sensational stories dominate, while nuance and context are often left behind. The danger is clear: when algorithms amplify perception over fact, they don’t just distort the narrative—they redefine it entirely. Consider the rise of “fake news” during election cycles or the selective visibility of certain voices in social movements. An algorithm prioritizing divisive content because it drives clicks might inadvertently tilt public perception, making a fringe viewpoint appear mainstream or a misleading headline go viral. In this reality, perception is not just shaped by the truth — it becomes the truth for many consumers. Without human judgment to interrogate these narratives, journalism risks becoming a tool of manipulation rather than a force for accountability. The human in the loop, then, isn’t just a safeguard; it’s the last line of defense against a world where algorithms define reality. The key question isn’t what to do about journalism’s changing landscape — it’s how these shifts reshape news-reporting standards. When algorithms dictate content visibility, core journalistic principles like accuracy, independence, and public trust are forced to adapt. Can these values survive in an engagement-driven system, or must they evolve? As technology continues to dominate, journalism faces a crossroads: reconcile traditional ideals with algorithmic realities, or risk losing its relevance and authority. Dr. Lauren Dwyer is an Assistant Professor with Mount Royal University's Information Design undergraduate program researching the role of emerging technologies in communication studies. Dr. Dwyer holds a PhD from Toronto Metropolitan University and York University’s joint Communication and Culture program, where she explored how social robots can be designed to enhance human communication and emotional experiences. Formerly SAIT’s Academic Chair for Artificial Intelligence and Data Analytics, she oversaw the development of programs that focus on utilizing data and AI to drive innovation in various fields. Her research interests currently lie at the intersection of emerging technology and human communication, particularly in relation to social robots and artificial intelligence. By approaching these complex topics through a communication studies lens, she has been able to shed new light on the potential impact of technology on human emotions and social connections. Lauren is a member of Digital Journal's Insight Forum.

COLLEGE FB NOTES

Prayers are pouring in for Minnesota Vikings quarterback Sam Darnold on Sunday afternoon. Javascript is required for you to be able to read premium content. Thanks for the feedback.

SHC directs Sindh government to submit details of cases against Dr Arif AlviPHILADELPHIA — Victoria Perrone wasn’t a spokesperson for Sen. John Fetterman’s 2022 Senate campaign. As his treasurer, she worked with numbers and spreadsheets. But when the campaign asked her to speak about her sister who relied in part on Medicaid at her Delaware County elementary school, she agreed. “My sister passed away from Ovarian Cancer in June and Dr. Oz became the Republican nominee,” she said on stage at Nether Providence Elementary School, sporting a ‘Made in Delco’ hoodie. “When I found out Dr. Oz lied to millions of TV viewers that one of his ‘miracle cures’ would decrease ovarian cancer by 75%, I got really mad, like Delco Mad.” Javascript is required for you to be able to read premium content. Please enable it in your browser settings.

New loan options for self-employed with stash of cashCancer Vaccines Pipeline Drugs Analysis Report, 2024: FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | Vaccitech, BrightPath Biotherapeutics, Hangzhou Neoantigen Therapeutics, Transgene, Enterome, Amal Therapeutics, OncoPep, Inc., Mod 12-09-2024 09:34 PM CET | Health & Medicine Press release from: DelveInsight Business Research (Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Cancer Vaccines pipeline constitutes 250+ key companies continuously working towards developing 300+ Cancer Vaccines treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. "Cancer Vaccines Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Cancer Vaccines Market. The Cancer Vaccines Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details. Some of the key takeaways from the Cancer Vaccines Pipeline Report: https://www.delveinsight.com/sample-request/cancer-vaccines-competitive-landscape?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr •Companies across the globe are diligently working toward developing novel Cancer Vaccines treatment therapies with a considerable amount of success over the years. •Cancer Vaccines companies working in the treatment market are Vaccitech, BrightPath Biotherapeutics, Hangzhou Neoantigen Therapeutics, Transgene, Enterome, Amal Therapeutics, OncoPep, Inc., Moderna Therapeutics, Gradalis, Inc., IO Biotech, Dendreon Pharmaceutical s LLC, and others, are developing therapies for the Cancer Vaccines treatment •Emerging Cancer Vaccines therapies in the different phases of clinical trials are- VTP-1100, BP-1209, iNeo-Vac-P01, TG4050, EO2401, ATP128, PVX-410, mRNA-4157, Vigil, IO102-IO103, Sipuleucel-T, and others are expected to have a significant impact on the Cancer Vaccines market in the coming years. •In September 2024, Moderna's mRNA cancer vaccine for solid tumors has shown early potential in interim data from a Phase I study. The mRNA specialist revealed that the vaccine has demonstrated initial signs of an immune response against cancer, prompting the activation of cancer-killing cells. Moderna is scheduled to present the findings from the first-in-human study of mRNA-4359 on September 14 at the European Society of Medical Oncology meeting. •In August 2024, Everest Medicines has launched an investigator-initiated clinical trial (IIT) for its personalized mRNA cancer vaccine, EVM16. The trial, named EVM16CX01, is being carried out at Peking University Cancer Hospital and Fudan University's Cancer Hospital in China. The study aims to assess the tolerability, safety, immunogenicity, and preliminary efficacy of EVM16, both as a standalone treatment and in combination with a PD-1 antibody, in patients with advanced or recurrent solid tumors. Cancer Vaccines Overview The emergence of cancer immunotherapy has significantly transformed cancer treatment, providing renewed optimism for cancer patients. While this therapy has shown remarkable success in certain cases, it is not universally effective, and there are various cancer types that do not exhibit a response to this treatment. Get a Free Sample PDF Report to know more about Cancer Vaccines Pipeline Therapeutic Assessment- https://www.delveinsight.com/report-store/cancer-vaccines-competitive-landscape?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr Emerging Cancer Vaccines Drugs Under Different Phases of Clinical Development Include: •VTP-1100: Vaccitech •BP-1209: BrightPath Biotherapeutics •iNeo-Vac-P01: Hangzhou Neoantigen Therapeutics •TG4050: Transgene •EO2401: Enterome •ATP128: Amal Therapeutics •PVX-410: OncoPep, Inc. •mRNA-4157: Moderna Therapeutics •Vigil: Gradalis, Inc. •IO102-IO103: IO Biotech •Sipuleucel-T: Dendreon Pharmaceutical s LLC Cancer Vaccines Route of Administration Cancer Vaccines pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as •Oral •Parenteral •Intravenous •Subcutaneous •Topical Cancer Vaccines Molecule Type Cancer Vaccines Products have been categorized under various Molecule types, such as •Monoclonal Antibody •Peptides •Polymer •Small molecule •Gene therapy Cancer Vaccines Pipeline Therapeutics Assessment •Cancer Vaccines Assessment by Product Type •Cancer Vaccines By Stage and Product Type •Cancer Vaccines Assessment by Route of Administration •Cancer Vaccines By Stage and Route of Administration •Cancer Vaccines Assessment by Molecule Type •Cancer Vaccines by Stage and Molecule Type DelveInsight's Cancer Vaccines Report covers around 300+ products under different phases of clinical development like •Late-stage products (Phase III) •Mid-stage products (Phase II) •Early-stage product (Phase I) •Pre-clinical and Discovery stage candidates •Discontinued & Inactive candidates •Route of Administration Further Cancer Vaccines product details are provided in the report. Download the Cancer Vaccines pipeline report to learn more about the emerging Cancer Vaccines therapies at: https://www.delveinsight.com/sample-request/cancer-vaccines-competitive-landscape?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr Some of the key companies in the Cancer Vaccines Therapeutics Market include: Key companies developing therapies for Cancer Vaccines are - GlaxoSmithKline PLC, Merck & Co. Inc., OSE Immunotherapeutics, Sanofi SA, Dendreon Pharmaceuticals LLC, Moderna Inc., Vaccitech Limited, Anixa Biosciences Inc., AstraZeneca PLC, Bristol Myers Squibb Company, F Hoffmann-La Roche AG (Genentech), Providence Therapeutics, eTheRNA immunotherapies, and others. Cancer Vaccines Pipeline Analysis: The Cancer Vaccines pipeline report provides insights into •The report provides detailed insights about companies that are developing therapies for the treatment of Cancer Vaccines with aggregate therapies developed by each company for the same. •It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Cancer Vaccines Treatment. •Cancer Vaccines key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. •Cancer Vaccines Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. •Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Cancer Vaccines market. The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc. Download Sample PDF Report to know more about Cancer Vaccines drugs and therapies- https://www.delveinsight.com/sample-request/cancer-vaccines-competitive-landscape?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr Cancer Vaccines Pipeline Market Drivers •Clinical trial data using personalized cancer vaccines are highly encouraging, cancer vaccines offer clinical benefits to patients with advanced metastatic disease, an attractive approach to synergize with currently available immune therapeutics strategies are some of the important factors that are fueling the Cancer Vaccines Market. Cancer Vaccines Pipeline Market Barriers •However, hurdles in developing appropriate methods to identify, refine and test candidate therapies, high cost associated with the research and other factors are creating obstacles in the Cancer Vaccines Market growth. Scope of Cancer Vaccines Pipeline Drug Insight •Coverage: Global •Key Cancer Vaccines Companies: Vaccitech, BrightPath Biotherapeutics, Hangzhou Neoantigen Therapeutics, Transgene, Enterome, Amal Therapeutics, OncoPep, Inc., Moderna Therapeutics, Gradalis, Inc., IO Biotech, Dendreon Pharmaceutical s LLC, and others •Key Cancer Vaccines Therapies: VTP-1100, BP-1209, iNeo-Vac-P01, TG4050, EO2401, ATP128, PVX-410, mRNA-4157, Vigil, IO102-IO103, Sipuleucel-T, and others •Cancer Vaccines Therapeutic Assessment: Cancer Vaccines current marketed and Cancer Vaccines emerging therapies •Cancer Vaccines Market Dynamics: Cancer Vaccines market drivers and Cancer Vaccines market barriers Request for Sample PDF Report for Cancer Vaccines Pipeline Assessment and clinical trials- https://www.delveinsight.com/sample-request/cancer-vaccines-competitive-landscape?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr Table of Contents 1. Cancer Vaccines Report Introduction 2. Cancer Vaccines Executive Summary 3. Cancer Vaccines Overview 4. Cancer Vaccines- Analytical Perspective In-depth Commercial Assessment 5. Cancer Vaccines Pipeline Therapeutics 6. Cancer Vaccines Late Stage Products (Phase II/III) 7. Cancer Vaccines Mid Stage Products (Phase II) 8. Cancer Vaccines Early Stage Products (Phase I) 9. Cancer Vaccines Preclinical Stage Products 10. Cancer Vaccines Therapeutics Assessment 11. Cancer Vaccines Inactive Products 12. Company-University Collaborations (Licensing/Partnering) Analysis 13. Cancer Vaccines Key Companies 14. Cancer Vaccines Key Products 15. Cancer Vaccines Unmet Needs 16 . Cancer Vaccines Market Drivers and Barriers 17. Cancer Vaccines Future Perspectives and Conclusion 18. Cancer Vaccines Analyst Views 19. Appendix 20. About DelveInsight Latest Reports: •Human Papillomavirus Hpv Market: https://www.delveinsight.com/report-store/human-papillomavirus-hpv-market •Blood Gas And Electrolyte Analyzers Market: https://www.delveinsight.com/report-store/blood-gas-and-electrolyte-analyzers-market •Interspinous Spacers Market: https://www.delveinsight.com/report-store/interspinous-spacers-market •Dengue Fever Market: https://www.delveinsight.com/report-store/dengue-fever-market •Chronic Hemodialysis Market: https://www.delveinsight.com/report-store/chronic-hemodialysis-market •Brucellosis Market: https://www.delveinsight.com/report-store/brucellosis-market •Childhood Atropine For Myopia Progression Market: https://www.delveinsight.com/sample-request/childhood-atropine-for-myopia-progression-market Contact Us: Gaurav Bora gbora@delveinsight.com +91-9650213330 Healthcare Consulting https://www.delveinsight.com/consulting-services About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach. This release was published on openPR.Report: Hornets F Grant Williams (knee) out for season